Joe Colletti
Welcome back to Pathfinders, a podcast series from RBC Capital Markets, where we explore the fast-moving world of biotech and pharma. I'm your host, Joe Colletti. We're on location at RBC Global Healthcare Conference in New York, and today I'm speaking with Chris Simms, Chief Commercial and Business Officer at 4D Molecular Therapeutics. 4D is advancing next-generation AAV genetic medicines for retinal diseases, including wet AMD and diabetic macular edema. As the company moves through phase three and prepares for potential commercialization, Chris brings a commercial perspective on how innovation reaches patients, physicians, and markets.
Chris, welcome to the podcast.
Chris Simms
It's great to be here, Joe. Good morning.
Joe Colletti
Chris, I want to start by talking about your background in ophthalmology and retina. What brought you to 4D at this stage of the company's growth?
Chris Simms
So, I have been in commercial leadership roles in ophthalmology, and more specifically in the retina side of ophthalmology for nearly 14 years now. Years ago, I worked on a leading anti-VEGF brand called Lucentis that was marketed by Genentech Roche. I also then spent time following Genentech at Novartis. I launched a drug called Beovu in the U.S. Following that, I made a departure from large pharma and spent time in a smaller biotech called Iberic Bio, where we had a phase three asset at the time for geographic atrophy. Had the good fortune of launching that medicine for GA patients in the U.S., and we ultimately were acquired by Astellas, which brings me to 4DMT. I joined 4DMT in 2024, so nearly a couple of years ago, and I was attracted to 4D by the opportunity that I believe to make a paradigm shifting change for the treatment of retinal diseases. This entire space has great medicines that are highly efficacious, but they're all bolus in nature, and most of the innovation has been incremental extensions in durability, so you take an eight week medicine and you extend it out by a couple of weeks from a patient durability perspective, and 4D has the promise and the potential we believe to make a paradigm shift for patients in the treatment burden, so instead of an incremental advancement in durability by a couple of weeks, which has been meaningful, we think we can actually reshape the entire treatment paradigm and potentially bring a treatment to patients that extends durability for months or years for many patients, and we actually think for some patients, and we've seen this in our phase two clinical data, patients that were getting upwards of 10 injections on average in a year got one injection of 4D150 and now, years later, they are injection-free. So that's exciting, it's paradigm shifting and the promise of that was certainly attractive to me to be a part of something that I think could make an indelible dent on this disease and really create a massive benefit for physicians and their patients.
Joe Colletti
That sounds very promising, and I know retina has seen major therapeutic innovation over the past two decades, and you mentioned the treatment burdens and the persistent challenge there. I wonder if you could elaborate a little bit. What else is still not working kind of well enough, particularly for patients and caregivers and practitioners today?
Chris Simms
Yeah, I think, when you think about how these treatments have been administered, the introduction of anti-VEGF therapy for retinal diseases happened about 2006, so we're almost 20 years beyond that time point. And these medicines are highly efficacious, but they're delivered through an intravitreal injection, so in other words, it's a needle in the eye, right? And they work really well; patients upon administration, certainly for wet AMD, they gain five to 10 letters of vision, which is incredibly meaningful. However, they have to come back on some frequency to get re-injected, so that injection in the eye has to happen at a frequency that's somewhat personalized to the patient. Some are as frequent as every four weeks, some get extended out, and they're on an 8, 12, or a 16 week schedule, but regardless of that, they have to come back at some frequency to get retreated. That results in treatment burden, and when you think about it, certainly from a wet AMD patient perspective, these patients are typically older, many of them are in their 80s. The burden of getting into the clinic, of having a caregiver bring them, the recovery time post treatment — all of that adds up, and unfortunately that treatment burden over time can mean that many patients either cease taking therapy altogether or their frequency of treatment starts to wane, and those effects we've seen in real world data will result in patients' vision starting to erode. So it's kind of unfortunate: you get this gain in vision upon initiation of therapy, which is life changing, but then because of the treatment burden you often get patients losing that vision when they get one, two, or three years out. So despite taking highly efficacious medicines, their vision is lost. We believe that if you have a 4D150-like product on board, which is constantly expressing an anti-VEGF therapy — it's always there, it's transduced retinal cells, and it's producing the medicine the patient needs on an ongoing basis — not only do you make a massive impact on the treatment burden reduction, you also have the potential for patients to hold on to that vision that they gain initially upon going on to therapy. So, clearly, from a patient perspective, that's life changing.
Joe Colletti
So, when you specifically look at wet AMD and DME, what makes those markets such a compelling opportunity for the next generation of these therapies?
Chris Simms
The markets are really well established. We believe globally, in our launch window horizon, the total value of the anti-VEGF market globally is probably going to be in the range of $20 billion and that's grown fairly consistently. One of the reasons for that growth is, one, there's been a continuation of innovation — so you've seen new brands come to market with the benefit of incremental durability, but you also have an aging and growing patient population. Age-related macular degeneration, by definition, is a disease that presents more in the elderly population, and as we know just from demographics, that population continues to grow as people age. So the market is projected to grow, we think, at a three-plus percent range for the foreseeable future, and the business model and the modality of treatment is fairly well established. So, there's a lot of things that are known: large market, highly diagnosed patient population, high propensity to treat this disease, and a market that's growing. The market opportunity and attractiveness is driven by the need, as we talked about earlier, to reduce the treatment burden — and that's where we think we fit in, and our value proposition is very differentiated.
Joe Colletti
Durability is such a major focus across the category. Commercially, what does it take to sort of shift the physician and patient thinking when it comes to the repeat injections to longer duration disease control?
Chris Simms
There are great analogs to that question. So again, we've seen new therapies come to market. The most recent has been a medicine by the name of Vabysmo, which is marketed by Roche Genentech, and EYLEA HD, or High-Dose, which is Regeneron's follow-on to their EYLEA franchise, and the benefit of both of those newer medicines has been an increment in durability. So, about 40 to 45% of patients on Vabysmo in their clinical studies were able to get out to 16 weeks, and some were at 12, and some were at eight. The growth has been driven by that incremental advancement in durability, and we know that's important. We see the uptake of these medicines. I think Vabysmo is on pace to be a four to $5 billion drug for Roche this year. And again, reminder — the benefit of the medicine is an extra week and a half to two weeks, maybe in aggregate data, and yet commercially it's been a success like that. So our simple view of the world is: if a week or two of added durability can have that level of commercial success, what's the potential for a medicine that can actually create durability measured by months, and we think years, for some patients? That's the foundation for our business case.
Joe Colletti
I want to talk about 4D150 a little further. Two-part question: you're operating in a very competitive environment right now. How is 4D150 differentiating itself? And second, 4D150 has the potential to be a global product. How are you thinking about the launch strategy across key markets?
Chris Simms
Great. So let me first talk about the differentiation of 4D150, then I'll go into the global opportunity and how we've thought that through. The differentiation starts with our science. The key hurdle with any gene therapy, certainly in ocular gene therapy, is that physicians, and thereby patients, have to have a strong belief in its safety profile. You need to demonstrate safety before you earn the right to talk about efficacy, and we think our safety is grounded in the fact that the company took the time, well before I showed up, to innovate and be very thoughtful as to how they selected and designed the vector. At the core of 4D150 is something we call the r100 vector. The r100 vector was raised in and selected in a non-human primate model, versus other therapies that often are developed in a mice model. So we think that matters, because it most resembles a human, and it was selected through a directed evolution process that we think allows it to be more targeted to the retinal cells that it has to transduce, and then by definition not transduce other cells that it should not be acting in. When you can do that in a highly targeted way, we think we can deliver a lower dose — our dose is 3×10, which is lower than other programs in development — and we think that has an implication for safety. As importantly, we generated pretty robust clinical data through our phase one/two program on 4D150, and our scientific thesis seems to be playing out in the clinic, where we have in-clinic trial safety data that resembles standard of care. The big thing in this space is the rate of intraocular inflammation. You don't want anything in the severe category, and the overall rate should be similar to what physicians see in standard of care — and that's what we've demonstrated. We think our most differentiating element is our safety profile, where we've shown IOI rates similar to what you would expect with EYLEA. From a global perspective, we think the unmet patient need is a global unmet patient need. In fact, when you think about the benefit of 4D150 — a safe, efficacious therapy that's constantly on board — there are certain countries around the world where access to care is not as easy as it is in the U.S. If patients can only get to see a retina doctor once or twice a year, having a therapy that's always there and always providing coverage could actually be more meaningful than in countries where you can get in to see a doctor more frequently. So we believe it's a global opportunity. Certainly, the U.S. is the largest and most valuable market, but we've designed our program for global application. Forefront One, our first phase three trial, completed enrollment as of the end of March — that's a North American trial, with 90% of the sites in the U.S. and the balance in Canada. Forefront Two is a global trial with U.S. sites, but also sites in Europe, South America, and Asia Pacific. We also announced last year that we've signed and agreed to provide Otsuka, a Japanese pharmaceutical company, with Asia Pacific rights for 4D150, while we retain the rights for every other market excluding Asia Pacific.
Joe Colletti
What do retina specialists need to see before they're going to be comfortable adopting a new treatment paradigm?
Chris Simms
Well, obviously, first you need to see safety, but you need to see that in a phase three setting. We're looking forward to the first half of next year when we'll read out our first phase three trial, Forefront One, and then approximately six months later, in the second half, we'll have our second phase three readout in Forefront Two. So that data is going to be really important to the retina community. Beyond that, once you get into a commercialized setting, I think they need to see a couple of things. They're going to need to see the demonstration of efficacy in the real world, and they're going to be looking for two things: safety — they'll want to see that real-world safety reflects what we hopefully show in our phase three trial — and how the medicine performs in the hardest-to-treat patients. Every new medicine launched in this therapeutic area, Vabysmo, EYLEA HD, Beovu a few years ago when I launched it, first gets used in the patients with the highest treatment need — those already getting injected 10, 11, 12 times a year. That's your first test. We feel really good about our odds in that test, because we've generated data already in our phase two program with patients that look exactly like that, so we're confident that in the real world, 4D150 would show up really well and create a meaningful treatment burden reduction. And then, of course, there's a bunch of non-clinical things around confidence and reimbursement that we'll have to work through. Luckily, I've spent most of the last 10 years of my career working on things to help with that.
Joe Colletti
I'm glad you mentioned that you've helped commercialize major retina and ophthalmology products in the past. What lessons from those launches do you think are most relevant as 4D moves closer to potential commercialization now?
Chris Simms
I think every launch is different. It's a dynamic marketplace. Ultimately, how you think about launch has to be a reflection of what you're trying to accomplish in the market you're looking to enter. But there are a couple of common things I think are always worth keeping in mind. First is start early — these things take time, and I don't think any launch that's been successful has had anyone look back and say, "Oh, we started too early." So start as early as you can, as early as your company is financially able to provide support. And then work closely with the retina community. We're so fortunate to work with a retina physician community that's highly engaged — they want to see advancements in science for their patients, and they're open to working with you early on. We've often had this philosophy of "for retina, by retina," which is: work with these physicians and their practice managers, they'll give you great insights, they'll help you understand what's important to their patients, and incorporating that learning as you prepare for commercialization won't steer you wrong.
Joe Colletti
I have one last question for you before we let you go off to your investor meetings at the conference today. When you look ahead, what do you think will define success for the next generation of retina therapies, and how is 4D really preparing for that future?
Chris Simms
Yeah, I love that question. We have a vision for 4D150 to be what we call a backbone therapy for retina, and that simply means that we think the majority of patients should have a safe, efficacious therapy always on board to treat their disease. The disease doesn't take a day off, and so we don't believe your therapy should take a day off either. So we're excited about a future treatment paradigm where the vast majority of patients have 4D150 on board, providing safe, efficacious treatment of their disease 24 hours a day, seven days a week, for the rest of their lives. And then for patients that need supplemental therapy — because it's a heterogeneous and very dynamic disease — doctors and their patients have a lot of really good bolus options to choose from to provide that supplementation. Our vision is that in the future, this disease is treated for the majority of patients with that backbone therapy approach, where patients are provided with constant coverage. And we hope, for the majority of patients, that the treatment of 4D150 will be the last needle in their eye that they'll ever need.
Joe Colletti
Chris, it's been a pleasure having you on the podcast — really insightful conversation, and we really wish you and 4D the best of luck as you work through the phase three trials and hopefully move into commercialization.
Chris Simms
Thanks, Joe. It's great to be here. Thanks for the invitation.
Joe Colletti
Thanks for listening to Pathfinders in Biopharma, brought to you by RBC Capital Markets. Please remember to subscribe to get more great content and be alerted about future episodes. This episode was recorded on May 19, 2026. If you'd like to learn more or continue the conversation, please contact your RBC representative or visit rbccm.com/biopharma. See you all next time.
This content is based on information available at the time it was recorded, and is for informational purposes only. It is not an offer to buy or sell or a solicitation, and no recommendations are implied. It is outside the scope of this communication to consider whether it is suitable for you and your financial objectives.